To risk stratify and shorten hospital stay in patients with spontaneous (resting) chest pain and a non-diagnostic electrocardiogram (ECG).
Introduction
The emergency room evaluation of patients with spontaneous (resting) chest pain and a non-diagnostic electrocardiogram (ECG) remains a challenge for the physician. In this time of financial constraints in particular, physicians are under pressure to reduce the frequency, intensity and length of hospital stay. To improve risk assessment several approaches have been proposed using decision algorithms [1, 2] , resting twodimensional echocardiography [3] and resting perfusion imaging with thallium-201 or technetium-99m [4] [5] [6] . All these approaches are aimed at identifying low-risk patients who could be sent home immediately. The consequences of inappropriate emergency room discharge of patients with true acute myocardial ischaemia, however, may be serious [7, 8] . Therefore, in daily clinical practice these sophisticated techniques are seldom used in the emergency room. Most physicians practice a conservative admission policy that results in a high level of admissions of patients with non-cardiac chest pain [9] . In-hospital observation, usually followed by some form of stress testing, may take several days, especially in patients initially considered at relatively high-risk. To shorten hospital stay and improve risk stratification we investigated the value of a structured protocol including serial creatine kinase enzyme measurements, continuous 12-lead ECG monitoring and early dobutamineatropine stress echocardiography followed by discharge of patients without inducible myocardial ischaemia. In patients with stable chest pain, dobutamine-atropine stress echocardiography has been shown to provide excellent diagnostic and prognostic information [10, 11] . The safety and predictive value of dobutamine-atropine stress echocardiography in patients with acute, spontaneous chest pain and a non-diagnostic ECG, however, is still relatively unknown [12] . This report addresses these issues.
Methods
Protocol (see Fig. 1 
)
Consecutive patients presenting to the emergency room with spontaneous (resting) chest pain within 12 h of presentation, unexplained by trauma, radiographic abnormality or extracardiac conditions that may induce myocardial ischaemia (Braunwald type IIIA angina) [13] , and without evidence of myocardial infarction or unstable angina by initial creatine kinase enzyme level and admission ECG were eligible for the study if they did not meet any of the following excluding criteria: (1) known ventricular tachyarrhythmias, (2) uncontrolled hypertension (d180/110 mmHg), (3) significant valvular heart disease, or (4) known significant coronary artery disease. Apart from a chest X-ray, ECG and creatine kinase enzyme measurement, clinical evaluation comprised patient history (including previous cardiac disease, chest pain characteristics [see Appendix I], coronary risk factors [see Appendix II]) and physical examination (see Appendix III). After hospitalization the 12-lead ECG was continuously monitored with a MIDA 1000 (Ortivus Medical, Täby, Sweden) or Mortara ST-100 (Mortara Instrument, Milwaukee, U.S.A.) system [14] . Creatine kinase enzyme measurements, including the MB isoform, were repeated at 6 h and 12 h. Dobutamine-atropine stress echocardiography was not performed in patients with myocardial necrosis, evidenced by creatine kinase >220 U . l 1 (or >110 and MB isoform >10%) and in patients with ECG changes during observation, conclusive for myocardial ischaemia (>0·1 mV ST-segment change, T wave inversion). In these patients the diagnosis myocardial infarction or unstable angina was established, respectively. In the absence of conclusive creatine kinase enzymes or ECG changes dobutamine-atropine stress echocardiography was performed between 12 and 48 h after admission (in patients with suspected coronary artery disease after a minimum of 12 h observation, in patients with known coronary artery disease, but of unknown actual significance, after 24 h). Patients who reached their target heart rate without inducible myocardial ischaemia were discharged within 24 h of the study (usually the same day of stress testing).
All patients were followed-up for 6 months. Inhospital and follow-up events noted were cardiac death, non-fatal myocardial infarction, unstable angina (defined as chest pain necessitating rehospitalization), coronary artery bypass surgery (CABG) and percutaneous transluminal coronary angioplasty (PTCA). Cardiac events were presented individually and in a cumulative fashion in which only the worst event in each patient was considered. If a patient underwent coronary angiography this was also noted. Significant coronary artery disease was defined as a diameter stenosis d50% in a major epicardial artery, scored by two observers blinded to the clinical data. In case of disagreement, quantitative coronary angiography was decisive [15] . The study protocol was approved by the hospital ethics committee.
Dobutamine-atropine stress echocardiography
Dobutamine was administered intravenously by an infusion pump with an infusion rate of 10 g . kg 1 . min 1 for 3 min, increasing by 10 g . kg 1 . min 1 every 3 min up to a maximum of 40 g . kg 1 . min 1 . In patients not achieving 85% of their age-and genderpredicted maximal heart rate and without symptoms or signs of myocardial ischaemia, atropine was administered, starting with 0·25 mg intravenously and repeated up to a maximum of 1·0 mg within 4 min with continuation of dobutamine infusion. Throughout the dobutamine infusion the ECG was continuously monitored (3 leads) and recorded (12 leads) at 1 min intervals. Reasons for interruption of the test were: severe angina, severe and/or extensive wall thickening abnormalities, symptomatic reduction in systolic blood pressure >40 mmHg from baseline, hypertension (blood pressure >240/120 mmHg), significant tachyarrhythmias, horizontal or downsloping ST-segment depression more than 0·2 mV at an interval of 80 ms after the J point compared with baseline, ST-segment elevation more than 0·1 mV in patients without previous myocardial infarction, and any serious side effect regarded as being due to dobutamine. Metoprolol was available to reverse the effects of dobutamine if patients did not revert spontaneously and quickly. The echocardiograms were recorded on videotape and digitized on optical disk (Vingmed Sound, Horten, Norway). Echocardiographic analysis of the left ventricular wall was performed according to the standardized 16-segments model [10] . Systolic wall thickening (and/or wall motion) was visually evaluated, and each segment was graded with a 5-point scoring model (1=normal; 2=mild hypokinesis; 3=severe hypokinesis; 4=akinesis; and 5=dyskinesis) during any dobutamine (or atropine) stage. Dobutamine-atropine stress echocardiography was considered non-diagnostic when peak heart rate was <85% of maximal in the absence of new or worsening wall thickening abnormalities. Dobutamine-atropine stress echocardiography was considered positive in patients with new or worsening wall thickening abnormalities at any dobutamine (or atropine) stage in d1 segment. Positive dobutamine-atropine stress echocardiography studies were further stratified into high-risk and low-risk studies. High-risk studies were defined as studies in which new or worsening wall thickening abnormalities occurred at a heart rate <70% of maximal or when they occurred in >1 vascular territory [10] .
Statistical analysis
Values were expressed as mean value standard deviation, when appropriate. Comparison between variables was performed with the Student's t-test for continuous variables and chi-square test for discrete variables. Differences of P<0·05 were considered significant. To identify independent predictors for cardiac events, multivariate logistic regression analysis with a forward and backward stepping algorithm was used (BMDP package) [16] . Variables included in this analysis were gender, age, history of coronary artery disease, history of exertional angina, admission ECG, need for intravenous nitroglycerin, dobutamine stress-induced angina and dobutamine-atropine stress echocardiography results.
Results

Patient characteristics
One-hundred and two consecutive patients gave informed consent and were included in the study. Mean age of the patients was 58 12 years (range 22 to 83), 67 were men (66%). There were 43 patients (42%) with suspected coronary artery disease and 59 (58%) with known coronary artery disease, but of unknown actual significance. All patients with suspected coronary artery disease had a chest pain score d6 (see Appendix I). Forty-eight patients (47%) had chest pain at admission; in the other 54 patients (53%) median time between last chest pain attack and admission was 2 h (range 1-12 h). Forty-one patients (40%) had a normal electrocardiogram (defined as sinus rhythm without pathological Q-waves, conduction disturbances, high QRS voltage, and ST-segment deviation or negative T-waves in leads I, II, aVL, aVF, and V 3 -V 6 . The other 61 patients (60%) had an abnormal, but, for acute myocardial ischaemia, non-diagnostic electrocardiogram (defined as absence of >0·1 mV new ST-segment change or new T-wave inversion). Relevant data of the 102 study patients are displayed in Table 1 .
Identification of patients with myocardial infarction or unstable angina
During observation the diagnosis evolving myocardial infarction was confirmed in four patients (4%) and the diagnosis unstable angina was established in nine patients (9% 
Haemodynamic and adverse effects of dobutamine-atropine stress
The remaining 89 patients without a definite diagnosis of either evolving myocardial infarction or unstable angina were referred for early dobutamine-atropine stress echocardiography for the evaluation of myocardial ischaemia. Mean time from hospitalization to dobutamine-atropine stress echocardiography was 33 12 h. In three patients (3%) with a poor echocardiographic window dobutamine-atropine stress echocardiography was not performed. In the remaining 86 patients dobutamine-atropine stress increased heart rate from 66 12 beats . min 1 to 134 16 beats . min 1 and systolic blood pressure from 136 19 mmHg to 145 26 mmHg. Test end-points were target heart rate in 59 patients (69%), maximal dose dobutamine-atropine in six patients (7%), severe and/or extensive wall thickening abnormalities in seven patients (8%), severe angina in six patients (7%), ST-segment changes in two patients (2%), ventricular tachyarrhythmia in two patients (2%), supraventricular tachyarrhythmia in one patient (1%), bradycardia with hypotension in one patient (1%), and nausea in two patients (2%). Most important arrhythmias during dobutamine infusion or recovery were non-sustained ventricular tachyarrhythmia in two patients (2%) and supraventricular tachyarrhythmia in four patients (5%). One additional patient developed sustained atrial flutter. The ventricular rate of this atrial flutter was well controlled with intravenous injection of 5 mg metoprolol. Typical angina was induced in 27 patients (31%). All responded well to intravenous injection of metoprolol (3-8 mg). Other side effects were nausea in 11 patients (13%), headache in four patients (5%) and anxiety in one patient (1%).
Predictors of positive dobutamine-atropine stress echocardiography
In the 86 patients who underwent dobutamine-atropine stress echocardiography, stress echocardiographic results were non-diagnostic in six patients (7%), negative in 44 patients (51%) and positive in 36 patients (42%). Nineteen of the latter 36 patients (53%) had high-risk dobutamine-atropine stress echocardiography. Clinical variables associated with positive dobutamine-atropine stress echocardiography were male gender (P<0·005, higher chest pain score (P<0·0001), a history of exertional angina (P<0·005), a history of coronary artery disease (P<0·0005), and an abnormal admission ECG (P<0·05) ( Table 2) .
Hospital stay and cardiac events in patients with poor or non-diagnostic dobutamine-atropine stress echocardiography
The three patients with a poor echocardiographic window had hospital stays of 48, 122 and 360 h, respectively. None of these patients had an in-hospital event.
During follow-up one patient returned with unstable angina. The six patients with a non-diagnostic study had a median hospital stay of 72 h (range 27-381 h). Three patients underwent in-hospital coronary angiography, in two patients coronary arteries were normal, one patient had one-vessel coronary artery disease and subsequently underwent PTCA. During follow-up another patient underwent coronary angiography which showed onevessel coronary artery disease, treated with PTCA.
Hospital stay in patients with diagnostic dobutamine-atropine stress echocardiography
The 44 patients with negative dobutamine-atropine stress echocardiography were discharged after a median hospital stay of 39 h (range 15-203 h). Three of these patients had a prolonged hospital stay despite negative dobutamine-atropine stress echocardiography. Two patients underwent coronary angiography, one because of clinically suspected significant coronary artery disease despite negative dobutamine-atropine stress echocardiography and one because of dilated cardiomyopathy. As seen in Fig. 2(a) , both patients were found to have normal coronary arteries. The third patient with prolonged hospital stay despite negative dobutamineatropine stress echocardiography underwent electrical cardioversion for non-dobutamine-atropine stress echocardiography related atrial fibrillation. When these three patients were excluded from analysis, median hospital stay was 37 h (range 15-104 h). 
Prediction of in-hospital events by clinical and stress test data
As seen in Fig. 2(a) , seven of 80 patients (9%) with diagnostic dobutamine-atropine stress echocardiography had an in-hospital cardiac event (CABG in two, PTCA in five). Clinical predictors of in-hospital events were (see Table 3 ) a history of exertional angina (P<0·005) and higher chest pain score (P<0·005). Stress test data associated with in-hospital events were positive dobutamine-atropine stress echocardiography (P<0·005), high-risk dobutamine-atropine stress echocardiography (P<0·0001) and stress-induced angina (P<0·001 
Prediction of follow-up events by clinical and stress test data
As seen in Fig. 2(b) , 11 of 80 patients (14%) with diagnostic dobutamine-atropine stress echocardiography had a cardiac event during follow-up (myocardial infarction in one, unstable angina in 10, CABG in three and PTCA in two; five patients had more than one event). Clinical predictors of follow-up events were (see Table 4 ) a history of exertional angina (P<0·05) and higher chest pain score (P<0·001). Stress test data associated with events were positive dobutamineatropine stress echocardiography (P<0·01), high-risk dobutamine-atropine stress echocardiography (P<0·01) and stress-induced angina (P<0·01). There were no significant differences in follow-up events in patients with and without in-hospital revascularization. At multivariate analysis the only significant predictor of events was positive dobutamine-atropine stress echocardiography (odds ratio 7·0; 95% confidence interval 1·4-35·8, P<0·01). Like all other stress modalities, negative dobutamineatropine stress echocardiography does not completely rule out the possibility of functionally important coronary artery disease. One 60-year-old male with a history of atypical angina and negative dobutamineatropine stress echocardiography underwent exercise ECG testing 2 weeks after discharge. Although this patient showed excellent exercise tolerance with adequate blood pressure response and absence of angina, arrhythmias or ST-segment changes, he suffered an inferoposterior myocardial infarction 2 weeks later. Subsequent coronary angiography revealed a significantly stenosed proximal right coronary artery, and mid left anterior descending coronary artery and an occluded left circumflex coronary artery. The left circumflex coronary artery and right coronary artery were retrogradely filled by collaterals from the left anterior descending coronary artery. The other patient with false negative dobutamine-atropine stress echocardiography 
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was a 73-year-old male with a history of typical, exertional angina. During dobutamine-atropine stress echocardiography 0·05 mV inferolateral ST-segment elevation occurred without angina. Dobutamine-atropine stress echocardiography results were scored as normal, although there was some doubt about the inferior wall, in particular because of relatively poor quality of the two-chamber view during peak dobutamine stress. One week after discharge this patient returned to the hospital with chest pain accompanied by significant inferolateral ST-segment elevation. Creatine kinase enzymes were negative; subsequent coronary angiography revealed a severe stenosis with thrombus of the proximal right coronary artery and significant stenosis of the left anterior descending coronary artery and left circumflex coronary artery. Clearly, this last patient was misdiagnosed as not having functionally important coronary artery disease. A specific benefit of dobutamine-atropine stress echocardiography was demonstrated in a patient without a history of coronary artery disease. His resting echocardiogram showed global hypokinesis of the left ventricular wall. During dobutamine stress, all myocardial segments showed sustained improvement in thickening. Subsequent coronary angiography revealed, (6) 2 (6) 5 (14) 7 ( (24) 7 (24) 1 (3) 7 (24) 2 (7) 7 ( as predicted by dobutamine-atropine stress echocardiography results, normal coronary arteries. Laboratory results showed elevated levels of thyroid hormone.
Discussion
Every day, emergency physicians are faced with the challenge of accurately diagnosing the cause of spontaneous chest pain in patients with a non-diagnostic ECG. Despite many vigorous efforts to identify patients with and without a true acute ischaemic coronary syndrome [1] [2] [3] [4] [5] [6] it is well known that a small percentage of patients is inadvertently released home, sometimes with serious (fatal) consequences [7, 8] . Therefore, in daily clinical practice most physicians practice a conservative admission policy which, in some patients with a final diagnosis of non-cardiac chest pain may require long in-hospital observation, especially in those patients initially considered at relatively high-risk (such as patients with known coronary artery disease).
Our protocol provides a rapid and structured approach for each patient that includes testing for evolving myocardial infarction with serial creatine kinase enzyme measurements, observation for resting ischaemia with continuous ST-segment trend monitoring, and dobutamine-atropine stress echocardiography to detect inducible myocardial ischaemia. Previous studies have shown that in patients with a nondiagnostic ECG the diagnosis of evolving myocardial infarction can be effectively established through measurement of creatine kinase enzyme within 12 h after See Table 3 for abbreviations.
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symptom onset [2, 17] . Continuous ST-segment trend monitoring provides observational data which reflect ischaemic status both in symptomatic and asymptomatic patients [18, 19] . If serial creatine kinase enzyme determination and continuous ST-segment trend monitoring demonstrate no evidence of resting ischaemia over a 12 h period, dobutamine-atropine stress echocardiography is performed. Although resting wall thickening abnormalities may reflect ischaemia, we did not use these abnormalities as a contra-indication to dobutamine-atropine stress echocardiography because in a heterogeneous patient population resting wall thickening abnormalities usually represent either a variant of normal, cardiomyopathy, or scar [20] . Indeed, in our patient population an abnormal resting echocardiogram was not predictive for cardiac events. Moreover, in cases of true resting ischaemia, further worsening of wall thickening will be seen directly (on-line) during low-dose dobutamine infusion [21] . Previous studies have demonstrated the safety and prognostic value of dobutamine-atropine stress echocardiography in patients with stable chest pain [10, 11] . In experienced hands, this stress modility offers many advantages over the usually performed exercise ECG test, such as increased accuracy for the detection of coronary artery disease [10] , independence of exercise capacity or resting ECG abnormalities, on-line monitoring of new wall thickening abnormalities (one of the earliest signs of ischaemia) [22] , detection of other cardiac causes of chest pain (valvular dysfunction, cardiomyopathy, pericarditis), and -in case of ischaemia -the possibility to neutralize the effects of dobutamine immediately with intravenous injection of a betablocker. All these characteristics make us believe that dobutamine-atropine stress echocardiography is a safer and better risk stratificating stress modality than exercise ECG testing in patients who are potentially ischaemic at rest.
Safety and feasibility
In accordance with previously published reports [10] dobutamine-atropine stress echocardiography could not be performed due to poor echocardiographic window quality only in a small minority of patients. Additionally, a few dobutamine-atropine stress echocardiography studies were non-diagnostic (peak heart rate <85% of maximal in absence of new or worsening wall thickening abnormalities). So, in approximately 90% of patients dobutamine-atropine stress echocardiography could be performed and yielded a diagnostic result. Although we often noticed more severe and/or extensive myocardial thickening abnormalities compared to prior studies in patients with stable chest pain, ventricular arrhythmias did not occur more frequently [10] . Importantly, all patients with signs or symptoms of severe myocardial ischaemia responded well to the injection of metoprolol, as did all patients with supraventricular tachyarrhythmias.
Clinical outcome
Patients with positive dobutamine-atropine stress echocardiography had (by protocol definition) a significantly higher in-hospital event rate than patients with negative dobutamine-atropine stress echocardiography. Despite intensive medical or invasive treatment of patients with positive dobutamine-atropine stress echocardiography, such a study also carried a significantly increased risk of cardiac events during follow-up. Negative dobutamine-atropine stress echocardiography was associated with a 6 months cardiac event rate of 5%, while patients with positive dobutamine-atropine stress echocardiography had an event rate of 25%. The predictive value of high-risk dobutamine-atropine stress echocardiography was even more striking. Patients with such a study more often had multi-vessel coronary artery disease compared to patients with low-risk dobutamine-atropine stress echocardiography and most of the events, both in-hospital as well as during 6 months follow-up, occurred in patients with high-risk dobutamine-atropine stress echocardiography. Of great importance is that dobutamine-atropine stress echocardiography more accurately characterized the risk of cardiac events than clinical data.
The number of events in patients with negative dobutamine-atropine stress echocardiography look favourable to the 7% hard event rate previously published from our centre in comparable patients with the final diagnosis of non-cardiac chest pain [23] . Importantly, in this latter publication hospital stay was more intensive, both in duration (in 10% of patients hospital stay was >5 days) and in the number and type of diagnostic procedures (sometimes including coronary angiography).
Comparison with other studies
Early risk stratification of patients with spontaneous chest pain has mainly involved resting nuclear perfusion imaging and exercise ECG testing. Several reports have shown the usefulness of thallium-210 or technetium-99m injection during or even after a spontaneous chest pain episode [4] [5] [6] . Although this technique has the advantage of not stressing a potentially unstable patient there are also some disadvantages such as radiation exposure, perfusion artifacts, costs and most importantly limited availability. Resting perfusion imaging obviously only recognizes patients at the highest risk, who in our study were partly identified by serial creatine kinase enzyme measurements and continuous ECG monitoring.
Usually, however, risk stratification is done by exercise ECG testing. Guidelines for exercise ECG testing state that this stress modality is contra-indicated in patients with (serious) chest pain at rest within the previous 48 h [24] . Nevertheless, several studies have shown evidence of the safety and efficacy of early exercise ECG testing in patients presenting with spontaneous chest pain to the emergency department [25] [26] [27] . However, these studies usually included patients with a very low pre-test probability of coronary artery disease, evidenced by the very low numbers of patients with positive tests, which were not uncommonly false positive. Most of the patients included in these studies probably required no cardiac work-up in the first place. In contrast, in our study over half of the included patients had evidence of myocardial ischaemia by serial creatine kinase enzymes, ECG monitoring or dobutamine-atropine stress echocardiography.
Recently, dobutamine-atropine stress echocardiography was proposed as a screening tool on an emergency room basis to risk stratify patients with spontaneous chest pain [12] . However, as with the published exercise ECG studies, the included patients were at very low risk, evidenced by the low numbers of patients with positive dobutamine-atropine stress echocardiography. Apart from logistic problems of performing dobutamineatropine stress echocardiography in the emergency room department, the major drawback of this emergency room approach is that patients with a true acute coronary syndrome are not given a second chance to show their myocardial ischaemia by means of creatine kinase enzyme rise or ECG monitoring. Moreover, dobutamine-atropine stress echocardiography was not performed in patients with resting wall thickening abnormalities. By not performing dobutamine-atropine stress echocardiography in patients with resting wall thickening abnormalities, patients in whom the wall thickening abnormalities represent actual myocardial ischaemia are protected against potential harmful dobutamine-atropine stress echocardiography. Unfortunately, this implies that all patients with actually non-ischaemic wall thickening abnormalities (in our study over a third of the patients) are not suitable for such a protocol and will be hospitalized for prolonged observation.
Limitations
Inherent to the study protocol was the availability of dobutamine-atropine stress echocardiography results to all physicians treating the patients. Knowledge of these results obviously affected management decisions regarding the aggressiveness of medical therapy or performance of coronary artery revascularization. As a result the predictive value of positive dobutamine-atropine stress echocardiography, and in particular of high-risk dobutamine-atropine stress echocardiography, for cardiac events such as PTCA or CABG could be anticipated. The number of patients with a hard cardiac event (death or myocardial infarction) was surprisingly low. Patients with spontaneous chest pain without evidence of ischaemia on the resting ECG constitute a relatively low-risk group, as opposed to high-risk unstable patients with ECG evidence of ischaemia [28] . On the other hand, the overall predictive value of positive dobutamine-atropine stress echocardiography for cardiac events during follow-up may have been underestimated because of the intensive medical and invasive treatment of patients with positive dobutamine-atropine stress echocardiography. The number of patients included in our study was relatively small. Therefore, conclusions, especially regarding safety, should be interpreted with caution.
Conclusions
Our results show that dobutamine-atropine stress echocardiography may safely select patients with spontaneous chest pain and a non-diagnostic ECG into lowand high-risk subsets for cardiac events. Other, larger studies are needed to confirm our findings and to assess the relative value and cost-effectiveness of this protocol in comparison to other protocols, involving other stress modalities. A study using troponin T as a chemical marker of myocardial injury [29] and comparing early dobutamine-atropine stress echocardiography with exercise stress testing or a more conservative strategy is currently in progress in Europe.
